Advertisement

Topics

Chi-Med Halts Phase III Study Early After Meeting Primary Endpoint

20:00 EDT 13 Jun 2019 | BioSpace

Based on the results, which were not disclosed at this time, the company said it will begin to plan for regulatory approval in China.

Original Article: Chi-Med Halts Phase III Study Early After Meeting Primary Endpoint

NEXT ARTICLE

More From BioPortfolio on "Chi-Med Halts Phase III Study Early After Meeting Primary Endpoint"

Advertisement
Quick Search
Advertisement
Advertisement